Exchange: NYSE·Updated 02:24 PM EDT
News
all
press releases
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion (AORT) delivered earnings and revenue surprises of 0.00% and +4.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Artivion Reports Second Quarter 2026 Financial Results
Artivion Reports Second Quarter 2026 Financial Results Artivion Reports Second Quarter 2026 Financial Results PR Newswire ATLANTA, Aug. 6, 2026 Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter...
PR Newswire
Steris (STE) Q1 Earnings Surpass Estimates
Steris (STE) delivered earnings and revenue surprises of +1.97% and -0.83%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Artivion to Participate in Upcoming Investor Conferences
Artivion to Participate in Upcoming Investor Conferences Artivion to Participate in Upcoming Investor Conferences PR Newswire ATLANTA, July 28, 2026 ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today...
PR Newswire
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results PR Newswire ATLANTA, July 23, 2026 ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion...
PR Newswire
Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2
Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2...
Yahoo! Finance: News
Intuitive Surgical, Inc. (ISRG) Q2 Earnings and Revenues Top Estimates
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Zacks
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.read more...
Benzinga
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis PR Newswire ATLANTA, June 29, 2026 ATLANTA, June 29, 2026 /PRNewswire/ --Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on...
PR Newswire

Advertisement|Remove ads.